Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chi-Med and Nestlé Form JV to Develop Chi-Med’s Lead Drug Candidate

publication date: Nov 28, 2012
Hutchison Chi-Med and Nestlé announced the formation of a major new JV based on Chi-Med’s expertise in traditional Chinese medicines. The JV, which will be called Nutrition Science Partners Limited, will focus on innovative gastrointestinal TCM-based medicines and nutritional products. Although the description sounds like an OTC venture, it also includes Chi-Med’s lead drug candidate, HMPL-004, a TCM-derived drug. HMPL-004 will soon begin Phase III trials as a treatment for ulcerative colitis and Crohn’s disease. More details....

Stock Symbol: (AIM: HCM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here